Clinical Trial Detail

NCT ID NCT02608268
Title Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

Therapies

Spartalizumab

Sabatolimab

Age Groups: adult

No variant requirements are available.